vitamin-b-12 and Small-Cell-Lung-Carcinoma

Lung cancer is the most frequently diagnosed neoplasia and represents the leading cause of cancer-related deaths worldwide. Due to this fact, efforts to improve patient survival through the introduction of novel therapies, as well as preventive actions, are urgently required. Considering this scenario, the antitumoral action of the composite formulation Ocoxin® oral solution (OOS), that contains several antitumoral compounds including antioxidants, was tested in small cell lung cancer (SCLC) in vitro and in vivo preclinical models. OOS exhibited anti-SCLC action that was both time and dose dependent. In vivo OOS decreased the growth of tumors implanted in mice without showing signs of toxicity. The antitumoral effect was due to inhibition of cell proliferation and increased cell death. Genomic and biochemical analyses indicated that OOS augmented p27 and decreased the functioning of several routes involved in cell proliferation. In addition, OOS caused cell death by activation of caspases. Importantly, OOS favored the action of several standard of care drugs used in the SCLC clinic. Our results suggest that OOS has antitumoral action on SCLC, and could be used to supplement the action of drugs commonly used to treat this type of tumor.

Topics: Administration, Oral; Animals; Antioxidants; Apoptosis; Ascorbic Acid; Cell Line, Tumor; Cell Proliferation; Dietary Supplements; Drug Compounding; Folic Acid; Gene Expression Regulation, Neoplastic; Humans; Mice; Pantothenic Acid; Plant Extracts; Proliferating Cell Nuclear Antigen; Small Cell Lung Carcinoma; Vitamin B 12; Vitamin B 6; Xenograft Model Antitumor Assays; Zinc Sulfate